Krems an der Donau, Austria, 30th January 2014 – Lacerta Technologies has hired a
new Chief Business Officer to strengthen the senior management team and to support
the ramping up of the company’s clinical development and commercialization efforts.
With more than 15 years of experience in the healthcare industry Dr. Peter Amersdorfer
has played a significant role in the development and execution of R&D and business
development strategies for several start-up companies both in the US and Europe. His
position with Lacerta Technologies has been newly established and will enable the Krems
based regenerative medicine company to bring its products to the international market.
The new serum coated bone graft products and related technologies are aimed for
orthopedic, dental or sports surgery use.
“Dr. Amersdorfer represents a critical addition to the team at this pivotal point in the
company’s transition from an R&D focus towards a more product- and market-driven
approach,” comments Dr. Zsombor Lacza, CEO of Lacerta Technologies. “Peter brings
considerable industry experience that will boost our abilities to build and advance our
product pipeline and identify new markets for Lacerta’s technologies.”
Profile Lacerta Technologies GmbH
Founded in 2012 and located in Krems an der Donau/Austria Lacerta Technologies GmbH is a clinical stage
regenerative medicine company aiming to translate research results into products for routine
clinical use. We put special emphasis on designing simple and affordable protocols allowing a wider
patient population to benefit from cell therapy.
Our current development projects include an innovative albumin-coated bone allograft and a point-of-care
device for the personalized production of autologous serum products.
Lacerta Technologies GmbH
A-3500 Krems an der Donau
Tel/Fax: +43 664 77 883 16206